Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

Mark E. Davis,Jonathan E. Zuckerman,Chung Hang J. Choi,David Seligson,Anthony Tolcher,Christopher A. Alabi,Yun Yen,Jeremy D. Heidel,Antoni Ribas
DOI: https://doi.org/10.1038/nature08956
IF: 64.8
2010-03-21
Nature
Abstract:Human RNAi therapyThe ability to downregulate specific genes using systemically delivered short RNA molecules and the cellular mechanism known as RNA interference has been shown previously in mouse and non-human primate models. Davis et al. have now demonstrated for the first time in humans that a short interfering RNA (siRNA) molecule can be systemically delivered using nanoparticles to a solid tumour. The siRNA mediates directed cleavage of its target mRNA, thereby also reducing the protein level. This proof-of-principle study confirms the potential of this technology as a human therapeutic.
multidisciplinary sciences
What problem does this paper attempt to address?